chartexchange

Merck KGaA is dropping a heart drug from its Silence deal after a rival's trial failed

Quartz | Nov 12, 2026 1:30 PM EST


Merck KGaA will not pursue an advanced study of zerlasiran, which lowers a cholesterol particle, after Novartis ended a similar drug

Read original article